PhRMA Conversations - Medicare Part D and its Promise

09.25.13 | By

In 2003, the Medicare Prescription Drug, Improvement, and Modernization Act was passed by Congress and signed into law by President George W. Bush. This landmark legislation created the Medicare prescription drug benefit (Part D) – a federal program that provides affordable drug coverage to millions of seniors and people with disabilities.

Patients Are Critical Collaborators In Parkinson's Disease

09.25.13 | By

Without patients who volunteer to participate in clinical trials, new medicines (including the 444 medicines in development to prevent and treat neurological disorders such as Parkinson’s) cannot be approved.  The Michael J.

Alzheimer's Disease and the Path Forward

Join Us for a Discussion about Challenges and Opportunities In Pre-Competitive Partnerships, Clinical Trial Enrollment and Public Policy

Conversations on Innovations in the Biopharmaceutical Pipeline

09.23.13 | By

With more than 5,000 medicines in development globally, the prospects for incredible breakthroughs in medicine – many of which may one day help those suffering from diseases that are currently untreatable – are exceedingly bright.

Recognizing World Alzheimer's Day

09.23.13 | By

As the nation recognizes World Alzheimer’s Day this Saturday, the federal government announced that it is awarding a $33.2 million grant to test an Alzheimer’s medicine in pre-symptomatic seniors (60 to 75 year olds) with two copies of the AD gene.  According to a 

Giving Patients Hope

09.20.13 | By

As Senior VP of Communications Matt Bennett noted on the Catalyst this week, years of hard work go into developing and testing new medicines, and this perseverance has resulted in great progress in clinical trial research.

FDA Spends $182k to Monitor Social Media While Biopharma Industry Waits for Social Media Guidance

09.20.13 | By

In this austere fiscal environment, I must admit to being a little surprised by the news that the Food and Drug Administration (FDA) is spending $182,000 on a tool to monitorwhat people are saying about the Agency on social media. 

Clinical Trials Data Sharing in Europe

09.20.13 | By

A new paper released this week highlights issues surrounding the discussions on clinical trial data & The paper Clinical Trials and Data Transparency: The Public Interest Case, highlights specific problems to the current draft European Medicines Agency (EMA). Among the problems highlighted were gaps in the protection of patient privacy, further bureaucratization of an already bureaucratic  system and conflicting policies on regulatory data protection. 

A Story of Hope - Ellie McGinn

09.19.13 | By

Delivering hope to millions of patients is the foundation of our industry. While the word 'hope' is highly personal to each patient, a common thread exists that unites all of us regardless of age, geographic location or socio-economic status. Without it, we would not be in a position to advance critical research that provides innovative new medicines to patients across the globe. By all accounts, 'hope' is the driver that keeps us looking forward.

Alzheimer's Research and Clinical Trials

09.19.13 | By

There have been a number of media reports over the last week about the challenges surrounding Alzheimer’s research.

Pages

Subscribe to RSS - Opinion